ASCO 2026: Updates in renal cancer

Mezigdomide plus carfilzomib dexamethasone improves PFS in R/R multiple myeloma

Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1 mutated AML with molecular failure

DVRd improves MRD negativity and PFS in transplant ineligible newly diagnosed multiple myeloma

Anselamimab reduces mortality and cardiovascular hospitalisation in kappa light chain AL amyloidosis

CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R large B cell lymphoma

Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia

ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation

Arsenic trioxide plus all trans retinoic acid improves QoL and reduces fatigue in high risk acute promyelocytic leukaemia

Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL

Selinexor plus ruxolitinib improves spleen response and survival in Janus kinase inhibitor naïve myelofibrosis

Fatigue in adult ITP is common despite adequate platelet counts and minimal bleeding